Key facts
- It has raised $149.6M across 2 recorded rounds; the latest was Early Stage VC ($46.0M) in Oct 2024.
- Notable investors include Creative Destruction Lab, MassChallenge, Springboard Enterprises, University of Toronto Entrepreneurship, Alexandria Venture Investments — 30 tracked in total.
- Axonis Therapeutics has filed 1 Form D with the SEC, most recently Nov 2024 ($46.0M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Axonis Therapeutics
Funding rounds
2 roundsAbout Axonis Therapeutics
Operator of a neuro-focused biotechnology company intended to develop medicines targeting a critical mediator of inhibitory neurotransmission in the brain. The company has developed a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery platform, enabling the healthcare industry to develop treatments for neurological disorders such as epilepsy, pain, and other central nervous system conditions.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 17
- Website
- axonis.us/
- Ownership
- Privately Held (backing)
Axonis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axonis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axonis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.